Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1615 1621 1625
This examiner grants 49% of resolved cases
Examiner Craigo has an allowance rate of 49.2% across 746 resolved cases in Art Unit 1615. This indicates a challenging environment in Tech Center 1600, where a minority of applications result in a grant. The median days to allowance of 1282 also points to a long and potentially difficult prosecution process. With 746 resolved cases, these statistics provide a robust and sobering outlook for applicants in this biotechnology sector.
The most significant data point is the interview lift of 38.2%. This is an exceptionally high figure, suggesting that interviews are extremely effective at overcoming rejections. For the 746 resolved cases, an interview appears to be the most critical factor in achieving an allowance. Practitioners should prioritize early and frequent communication to navigate the 1282-day median timeline and improve their 49.2% success rate. The 38.2% lift is a clear signal that the examiner is highly responsive to verbal arguments and collaborative problem-solving. Utilizing this tool is essential for any applicant hoping to secure a patent in this rigorous art unit.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18796716 | HEMOSTATIC COMPOSITIONS AND RELATED METHODS | Non-Final OA | Boston Scientific Scimed, Inc. |
| 18287475 | BIORESORBABLE IMPLANT MATERIALS AND METHODS OF MAKING THE SAME | Final Rejection | Georgia Tech Research Corporation |
| 18709316 | GRANULE COMPRISING ENCAPSULATED ACTIVE INGREDIENTS | Non-Final OA | DSM IP ASSETS B.V. |
| 18710555 | ULTRA PH-SENSITIVE MICELLES ENCAPSULATING CYTOKINES FOR TREATMENT OF CANCER | Non-Final OA | The Board of Regents of The University of Texas System |
| 18708527 | COMPOSITIONS HAVING CHAIR-SIDE HANDLING PROPERTIES FOR DENTAL AND SOFT TISSUE APPLICATIONS | Non-Final OA | EVONIK OPERATIONS GMBH |
| 18684938 | COMPOSITION FOR CARING FOR KERATIN MATERIALS | Final Rejection | L'OREAL |
| 18381401 | BUFFERED ADHESIVE COMPOSITIONS FOR SKIN-ADHERING MEDICAL PRODUCTS | Final Rejection | HOLLISTER INCORPORATED |
| 18948385 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | Non-Final OA | PEPTILOGICS, INC. |
| 18832725 | LIQUID FORMULATION COMPRISING A FUSION PROTEIN INCLUDING a-GALACTOSIDASE A | Non-Final OA | HANMI PHARM. CO., LTD. |
| 18553893 | ANTIMICROBIAL ELUTING AIRWAY DEVICES | Final Rejection | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18684910 | CELL MATRIX NERVE GRAFT FOR REPAIRING PERIPHERAL NERVE INJURY AND PREPARATION METHOD THEREOF | Non-Final OA | NANTONG UNIVERSITY |
| 18258518 | METHOD FOR TREATING PAIN USING VANADIUM COMPOUNDS | Non-Final OA | SHENZHEN FANGSHENGTAI MEDICAL TECHNOLOGY CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy